Helicon Group Limited

Asian Activities Report for October 18, 2011 includes: Algae. Tec Limited (ASX:AEB) has received regulatory approvals for the development of an algae demonstration plant in the south of Sydney; Helicon Group Limited (ASX:HCG) today announces the execution of a definitive agreement to acquire Aspen Medisys; Alkane Resources Limited (ASX:ALK) has signed an agreement with the NSW Government to receive financial assistance for the infrastructure development of the Tomingley Gold Project in the Central West of NSW; Transerv Energy Limited (ASX:TSV) has completed the initial 10-day test of the Upper Zone at the Warro-4 onshore well in Western Australia; Augur Resources Limited (ASX:AUK) reports extensive gold and copper results from the Randu Kuning prospect, Wonogiri project in Central Java.

HELICON GROUP LIMITED (ASX:HCG) announced today that it has implemented a restructuring and cost reduction program in response to the ongoing delays by the Chinese regulatory authority, the State Food and Drug Administration (SFDA), to grant regulatory approvals across the board and an anticipated slow down in economic activity in China.

Helicon Group Limited (ASX:HCG) is pleased to announce that earlier this month the Chinese State Food and Drug Administration (SFDA) granted approval for the skin regeneration concept and device, ReCell(R), for sale in China.

HELICON GROUP LIMITED (ASX:HCG) today announced that the Chinese State Food and Drug Administration (SFDA) has granted approval for the skin regeneration concept and device, ReCell(R).

Helicon Group (ASX:HCG) wishes to inform the market of the release of a third party research report, compiled by Money Cat Consulting, which focuses on the company's core competencies, business model and product acquisitions.

Helicon Group Limited (ASX: HCG) is a pharmaceutical and healthcare company with an innovative strategy, listed on the Australian Securities Exchange. Its business is to identify and exploit niche market opportunities in the specialty pharmaceutical and healthcare markets of China and North Asia and to participate in the significant growth that has been projected for those markets over the next 20 years.

HELICON GROUP LIMITED (ASX: HCG) announced today that it had acquired the exclusive licensing rights from EUSA Pharma to Collatamp(R) G for the Chinese market.

HELICON GROUP LIMITED (ASX: HCG) is pleased to announce the appointment of Anita Wehrli to the position of Business Development Manager based in Switzerland.

HELICON GROUP LIMITED (ASX: HCG) today announced the appointment of Aleksandra Gajda to the position of Stakeholder Relations Manager.

With the regulatory process well underway in China, Helicon (ASX: HCG) has put the ReCell(R) pre-marketing program into gear with a number of activities over the last few months.